> Amarantus BioScience Holdings ($AMBS) snatched up neuro diagnostics outfit DioGenix in a deal worth up to $10.9 million to get its hands on the company's next-generation sequencing test for multiple sclerosis. Statement (PDF)
> Illumina ($ILMN) unveiled three new sequencing systems, the HiSeq x Five, the HiSeq 3000 and 4000, and forecast 20% revenue growth in 2015. Story (reg. req.)
> Roche ($RHHBY) won FDA approval for the first test that simultaneously screens for HIV, hepatitis C and hepatitis B in blood samples. Story
> Foundation Medicine ($FMI) launched the newest version of its Interactive Cancer Explorer (ICE) physician portal, ICE 2, which allows doctors to access patients' test results on a tablet, computer or mobile device and compare treatment information for individuals with similar genomic profiles. Release
> Myriad Genetics ($MYGN) won a CE mark for its Tumor BRACAnalysis companion diagnostic test that identifies which patients are a good fit for AstraZeneca's ($AZN) poly ADP-ribose polymerase (PARP) inhibitor Lynparza. More
> Exact Sciences ($EXAS) reported preliminary Q4 2014 revenue, including $1.5 million for its noninvasive colorectal cancer test, Cologuard. More
And Finally... Two medical organizations recommended testing for HPV to screen women ages 25 and older for cervical cancer before using a Pap test. Story